The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
© 2024 TheOutpost.AI All rights reserved
Curated by THEOUTPOST
On July 23, 2024
3 Sources
[1]
Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split
Following the reverse share split, the Company will have approximately 5,079,000 Ordinary Shares issued and outstanding REHOVOT, Israel, July 23, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company" or "Evogene"), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, announced today that a reverse share split of its issued and outstanding Ordinary Shares, at a ratio of 1-for-10, is expected to be implemented after market close on July 24, 2024. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-reverse split basis at the market open on July 25, 2024, and on the Tel Aviv Stock Exchange at the market open on July 28, 2024, in each case under the Company's existing trading symbol "EVGN". The reverse share split was approved by the Company's shareholders at the Company's Annual Meeting of Shareholders held on June 13, 2024, to be effected at the board of directors' discretion within approved parameters. Following the implementation of the reverse split, the Company's registered share capital under the Company's amended and restated articles of association, as currently in effect (the "Articles"), which as of the date hereof consists of NIS 3,000,000 divided into 150,000,000 Ordinary Shares of NIS 0.02 par value each, will be adjusted to consist of NIS 3,000,000 divided into 15,000,000 Ordinary Shares of NIS 0.2 par value each. The reverse split will adjust the number of issued and outstanding Ordinary Shares of the Company from approximately 50,790,000 Ordinary Shares to approximately 5,079,000 Ordinary Shares (subject to any further adjustments based on the treatment of fractional shares). No fractional Ordinary Shares will be issued as a result of the reverse split. In accordance with the Company's Articles, all fractional shares shall be rounded to the nearest whole ordinary share, such that only shareholders holding fractional consolidated shares of more than half of the number of shares which consolidation constitutes one whole share, shall be entitled to receive one consolidated share. No cash will be paid with respect to any fractional shares. In addition, proportionate adjustments will be made to the number of shares issuable upon the exercise of all outstanding options entitling the holders to purchase Ordinary Shares (with a reciprocal increase in the per share exercise price) and to the number of Ordinary Shares underlying outstanding Restricted Share Units (RSUs). About Evogene Ltd.: Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its five subsidiaries including: This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "hopes" "intends", "anticipates", "plans", "believes", "scheduled", "estimates", "demonstrates" or words of similar meaning. For example, Evogene is using forward-looking statements in this press release when it discusses its plan to effectuate a reverse share split of its ordinary shares and the timing related to such reverse share split. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the current war between Israel and each of Hamas and Hezbollah, the possibility of escalation to a wider regional war, and any worsening of the situation in Israel such as further mobilizations or escalation in the northern border of Israel and those risk factors contained in Evogene's reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. View original content:https://www.prnewswire.com/news-releases/evogene-announces-expected-implementation-of-1-for-10-reverse-share-split-302204000.html
[2]
Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split - Evogene (NASDAQ:EVGN)
Following the reverse share split, the Company will have approximately 5,079,000 Ordinary Shares issued and outstanding REHOVOT, Israel, July 23, 2024 /PRNewswire/ -- Evogene Ltd. EVGN EVGN (the "Company" or "Evogene"), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, announced today that a reverse share split of its issued and outstanding Ordinary Shares, at a ratio of 1-for-10, is expected to be implemented after market close on July 24, 2024. The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-reverse split basis at the market open on July 25, 2024, and on the Tel Aviv Stock Exchange at the market open on July 28, 2024, in each case under the Company's existing trading symbol "EVGN". The reverse share split was approved by the Company's shareholders at the Company's Annual Meeting of Shareholders held on June 13, 2024, to be effected at the board of directors' discretion within approved parameters. Following the implementation of the reverse split, the Company's registered share capital under the Company's amended and restated articles of association, as currently in effect (the "Articles"), which as of the date hereof consists of NIS 3,000,000 divided into 150,000,000 Ordinary Shares of NIS 0.02 par value each, will be adjusted to consist of NIS 3,000,000 divided into 15,000,000 Ordinary Shares of NIS 0.2 par value each. The reverse split will adjust the number of issued and outstanding Ordinary Shares of the Company from approximately 50,790,000 Ordinary Shares to approximately 5,079,000 Ordinary Shares (subject to any further adjustments based on the treatment of fractional shares). No fractional Ordinary Shares will be issued as a result of the reverse split. In accordance with the Company's Articles, all fractional shares shall be rounded to the nearest whole ordinary share, such that only shareholders holding fractional consolidated shares of more than half of the number of shares which consolidation constitutes one whole share, shall be entitled to receive one consolidated share. No cash will be paid with respect to any fractional shares. In addition, proportionate adjustments will be made to the number of shares issuable upon the exercise of all outstanding options entitling the holders to purchase Ordinary Shares (with a reciprocal increase in the per share exercise price) and to the number of Ordinary Shares underlying outstanding Restricted Share Units (RSUs). About Evogene Ltd.: Evogene Ltd. EVGN EVGN is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its five subsidiaries including: Biomica Ltd. (www.biomicamed.com) developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI; Lavie Bio Ltd. (www.lavie-bio.com) - developing and commercially advancing, microbiome based ag-biologicals powered by MicroBoost AI; AgPlenus Ltd. (www.agplenus.com) -developing next generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI; Casterra Ag Ltd. (www.casterra.co)- developing and marketing superior castor seed varieties producing high yield and high-grade oil content, on an industrial scale for the biofuel and other industries powered by GeneRator AI. For more information, please visit: www.evogene.com. This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "hopes" "intends", "anticipates", "plans", "believes", "scheduled", "estimates", "demonstrates" or words of similar meaning. For example, Evogene is using forward-looking statements in this press release when it discusses its plan to effectuate a reverse share split of its ordinary shares and the timing related to such reverse share split. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the current war between Israel and each of Hamas and Hezbollah, the possibility of escalation to a wider regional war, and any worsening of the situation in Israel such as further mobilizations or escalation in the northern border of Israel and those risk factors contained in Evogene's reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. Investor Relations Contact Rachel Pomerantz Gerber I Head of Investor Relations at Evogene rachel.pomerantz@evogene.com I Tel: +972-8-9311901 Logo - https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg View original content:https://www.prnewswire.com/news-releases/evogene-announces-expected-implementation-of-1-for-10-reverse-share-split-302204000.html SOURCE Evogene Market News and Data brought to you by Benzinga APIs
[3]
Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split By Investing.com
Following the reverse share split, the Company will have approximately 5,079,000 Ordinary Shares issued and outstanding , /PRNewswire/ -- Evogene Ltd . (Nasdaq: NASDAQ:EVGN) (TASE: EVGN) (the "Company" or "Evogene"), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, announced today that a reverse share split of its issued and outstanding Ordinary Shares, at a ratio of 1-for-10, is expected to be implemented after market close on . The Company's Ordinary Shares will begin trading on the Nasdaq Capital Market on a post-reverse split basis at the market open on , and on the Tel Aviv Stock Exchange at the market open on , in each case under the Company's existing trading symbol "EVGN". The reverse share split was approved by the Company's shareholders at the Company's Annual Meeting of Shareholders held on , to be effected at the board of directors' discretion within approved parameters. Following the implementation of the reverse split, the Company's registered share capital under the Company's amended and restated articles of association, as currently in effect (the "Articles"), which as of the date hereof consists of NIS 3,000,000 divided into 150,000,000 Ordinary Shares of par value each, will be adjusted to consist of divided into 15,000,000 Ordinary Shares of par value each. The reverse split will adjust the number of issued and outstanding Ordinary Shares of the Company from approximately 50,790,000 Ordinary Shares to approximately 5,079,000 Ordinary Shares (subject to any further adjustments based on the treatment of fractional shares). No fractional Ordinary Shares will be issued as a result of the reverse split. In accordance with the Company's Articles, all fractional shares shall be rounded to the nearest whole ordinary share, such that only shareholders holding fractional consolidated shares of more than half of the number of shares which consolidation constitutes one whole share, shall be entitled to receive one consolidated share. No cash will be paid with respect to any fractional shares. In addition, proportionate adjustments will be made to the number of shares issuable upon the exercise of all outstanding options entitling the holders to purchase Ordinary Shares (with a reciprocal increase in the per share exercise price) and to the number of Ordinary Shares underlying outstanding Restricted Share Units (RSUs). About Evogene Ltd.: Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its five subsidiaries including: This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "hopes" "intends", "anticipates", "plans", "believes", "scheduled", "estimates", "demonstrates" or words of similar meaning. For example, Evogene is using forward-looking statements in this press release when it discusses its plan to effectuate a reverse share split of its ordinary shares and the timing related to such reverse share split. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the current war between and each of Hamas and Hezbollah, the possibility of escalation to a wider regional war, and any worsening of the situation in such as further mobilizations or escalation in the northern border of and those risk factors contained in Evogene's reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. Logo - https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg
Share
Share
Copy Link
Evogene Ltd., a leading computational biology company, has announced plans to implement a 1-for-10 reverse share split of its ordinary shares. The move aims to regain compliance with Nasdaq's minimum bid price requirement.
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), a prominent computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, has announced its intention to implement a 1-for-10 reverse share split of its ordinary shares 1. This strategic move is expected to take effect at the opening of trading on July 17, 2024, subject to shareholder approval at the Company's upcoming Annual General Meeting of Shareholders.
The primary objective of this reverse share split is to regain compliance with the Nasdaq Stock Market's minimum bid price requirement 2. By consolidating shares, Evogene aims to increase its share price, potentially attracting a broader range of investors and improving overall market perception.
Upon implementation, every ten ordinary shares of Evogene will be automatically combined into one ordinary share 3. This will significantly reduce the number of outstanding ordinary shares from approximately 41.2 million to roughly 4.1 million. It's important to note that this change will not affect the Company's authorized share capital or the par value of its ordinary shares.
Shareholders should be aware that no fractional shares will be issued as a result of the reverse share split. Instead, all fractional shares will be rounded up to the nearest whole number of shares [1]. The Company has assured that the reverse split will not impact any shareholder's percentage ownership interest or voting power, except for minimal effects resulting from the rounding up of fractional shares.
Following the reverse share split, Evogene's ordinary shares will continue to trade on the Nasdaq Global Market and the Tel Aviv Stock Exchange under the existing symbol "EVGN" [2]. However, the shares will be assigned a new CUSIP number, reflecting the corporate action.
The implementation of the reverse share split is contingent upon shareholder approval at Evogene's Annual General Meeting of Shareholders, scheduled for July 10, 2024 [3]. If approved, the reverse split is expected to become effective at the opening of trading on July 17, 2024. Shareholders of record will receive formal notification from the Company's transfer agent, American Stock Transfer & Trust Company, LLC, with specific instructions regarding the reverse share split.
Reference
[1]
[2]
ICL Group Ltd. and Lavie Bio Ltd. have announced a significant breakthrough in developing sustainable agricultural solutions using artificial intelligence. This collaboration aims to enhance crop resilience and reduce chemical inputs in farming.
3 Sources
Tevogen Bio's CEO Ryan Saadi expresses confidence in the company's growth strategy and reaffirms commitment to advancing precision T cell technology. The biotech firm aims to address large and underserved global health challenges.
2 Sources
Evaxion Biotech announces significant progress in both its gonorrhea vaccine candidate and cancer vaccine trials, showcasing the potential of its AI-powered drug discovery platform.
2 Sources
Evergreen Corporation and Forekast Limited have entered into a definitive business combination agreement. The merger aims to create a leading global provider of AI-powered forecasting and decision intelligence solutions.
2 Sources
Nauticus Robotics, a developer of autonomous robots for ocean industries, has announced a 1-for-36 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and attract a broader range of investors.
2 Sources